Morningstar27d
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™, Pioneering Real-Time Detection of Residual Breast Cancer During Lumpectomy
Unlike other detection systems that only evaluate tissue after it has been surgically removed, LumiSystem™ allows for real-time visualization of cancer inside the breast. This enables surgeons ...
abc2727d
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™, Pioneering Real-Time Detection of Residual Breast Cancer During Lumpectomy
NEWTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today ...
Hosted on MSN25d
Lumicell launches LumiSystem in US for real-time cancer detection
Lumicell has announced the launch of LumiSystem for real-time cancer detection, making it commercially available in the US. The system combines the FDA-approved Lumisight optical imaging agent and ...
BioSpace27d
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™, Pioneering Real-Time Detection of Residual Breast Cancer During Lumpectomy
Jan. 27, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the U.S. commercial availability and ...
Targeted Oncology24d
A Real-Time Cancer-Detecting System for Breast Cancer Goes Live
The LumiSystem is now commercially available in the US for breast cancer detection. The device uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other ...
Targeted Oncology27d
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results. The FDA has granted ...